Skip to main content
. 2005 Jun 7;93(1):46–53. doi: 10.1038/sj.bjc.6602653

Table 2. Summary of all patients and treatment administered.

  Cycle # and dose of PEG-LD (mg m−2)
Patient # 1a 2 3 4 5 6 7 8 9 10 11 12 13 14
 1 20 8 12 16 20                  
 2 20 16 20 24 18 18 18 18 18 13.5 13.5 13.5 13.5 13.5
 3 20 20 20 20                    
 4 20 20                        
 5 20 20                        
 6 20 22 22 16.5 16.5 16.5 16.5 12.4 12.4 12.4 12.4 12.4    
 7 22 22 22 22                    
 8 22 22 22 22                    
 9 25 25 25 25                    
10 25 25                        
11 25 25                        
12 25 25 25 25 18.75 18.75 18.75 18.75 18.75 18.75 18.75 18.75    
13 25 25                        
14 25 25 25 25 25 18.75 18.75 18.75 18.75 18.75 14.06 14.06 14.06 14.06
a

All patients received PEG-LD (pegylated liposomal doxorubicin) alone for the cycle 1 and PEG-LD in combination with valspodar for all other cycles.